is semaglutide compound fda-approved FDA crackdown on off-brand Ozempic products set to take effect, threatening supply and access for many The Risks of Compounded Semaglutide

Like other GLP-1 medications, weight regain is expected if treatment is discontinued

However, in the coming years, dosing is expected to become more tailored, differentiating between weight loss and weight maintenance, adjusting for specific chronic conditions, and addressing cases where patients dont need weight loss but are at risk for heart disease for instance

doi:10.1016/j.freeradbiomed.2010.12.020 43

Market Sizing Tools to assess growth opportunities and demand for the tech

Ozempic has been linked to rare but serious conditions, such as pancreatitis, gallbladder disease, and possible thyroid complications